These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19548062)

  • 1. Bone metabolism after cinacalcet administration in patients with secondary hyperparathyroidism.
    Yano S; Suzuki K; Sumi M; Tokumoto A; Shigeno K; Himeno Y; Sugimoto T
    J Bone Miner Metab; 2010; 28(1):49-54. PubMed ID: 19548062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism.
    Kurajoh M; Inaba M; Okuno S; Nagayama H; Yamada S; Imanishi Y; Ishimura E; Shoji S; Yamakawa T; Nishizawa Y
    Osteoporos Int; 2011 Mar; 22(3):923-30. PubMed ID: 20449572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Akiba T; Akizawa T; Tsukamoto Y; Uchida E; Iwasaki M; Koshikawa S;
    Ther Apher Dial; 2008 Apr; 12(2):117-25. PubMed ID: 18387159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet.
    Haq N; Chaaban A; Gebran N; Khan I; Abbachi F; Hassan M; Bernsen R; Abouchacra S
    Int Urol Nephrol; 2014 Jan; 46(1):113-9. PubMed ID: 23529273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of cinacalcet combined with low-dose calcitriol on clinical outcome and bone metabolism in patients with severe secondary hyperparathyroidism].
    Yuan F; Chen X; Wang C; Zhou A; Liu H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1169-1173. PubMed ID: 29093248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism.
    Yajima A; Akizawa T; Tsukamoto Y; Kurihara S; Ito A;
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S38-43. PubMed ID: 19032526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Shigematsu T; Akizawa T; Uchida E; Tsukamoto Y; Iwasaki M; Koshikawa S;
    Am J Nephrol; 2009; 29(3):230-6. PubMed ID: 18797166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].
    Jean G; Vanel T; Terrat JC; Hurot JM; Lorriaux C; Mayor B; Deleaval P; Vovan C; Chazot C
    Nephrol Ther; 2010 Apr; 6(2):105-10. PubMed ID: 20185380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
    Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
    Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroidectomy leads to decreased blood lead levels in patients with refractory secondary hyperparathyroidism.
    Chu P; Wu CC; Chen CC; Lu KC
    Bone; 2012 May; 50(5):1032-8. PubMed ID: 22373954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism.
    Lu KC; Ma WY; Yu JC; Wu CC; Chu P
    Clin Endocrinol (Oxf); 2012 May; 76(5):634-42. PubMed ID: 22007930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
    Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism.
    Tsuruta Y; Okano K; Kikuchi K; Tsuruta Y; Akiba T; Nitta K
    Clin Exp Nephrol; 2013 Feb; 17(1):120-6. PubMed ID: 22833360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of cinacalcet withdrawal in Australian dialysis patients.
    Ruderman I; Holt SG; Kirkland GS; Maslen S; Hawley CM; Oliver V; Krishnasamy R; Gray NA; Talaulikar GS; Nelson CL; Rajaram Y; Gock H; Au E; Elder GJ; Mainra R; Toussaint ND
    Intern Med J; 2019 Jan; 49(1):48-54. PubMed ID: 29992701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism.
    Schwarz A; Merkel S; Leitolf H; Haller H
    Transplantation; 2011 Mar; 91(5):560-5. PubMed ID: 21192318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
    Li D; Shao L; Zhou H; Jiang W; Zhang W; Xu Y
    Endocrine; 2013 Feb; 43(1):68-77. PubMed ID: 22669774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targets for parathyroid hormone in secondary hyperparathyroidism: is a "one-size-fits-all" approach appropriate? A prospective incident cohort study.
    Laurain E; Ayav C; Erpelding ML; Kessler M; Briançon S; Brunaud L; Frimat L
    BMC Nephrol; 2014 Aug; 15():132. PubMed ID: 25123022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.